# US 2015/0105358 A1 · Combinations of histone deacetylase inhibitors and immunomodulatory drugs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105358 A1
- Document ID: US20150105358A1
- Status: Published application
- Kind: A1
- Application number: 14/508,072
- Filed: 2014-10-07
- Published: 2015-04-16
- Earliest claimed: 2013-10-11
- Assignees: Acetylon Pharmaceuticals, Inc.
- Inventors: Steven Norman Quayle; Simon Stewart Jones; Kenneth C. Anderson; Teru Hideshima
- Web page: https://patentgrep.com/patent/US20150105358A1

## CPC

- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/454: containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A61K 31/573: substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
- A61P 19/00: Drugs for skeletal disorders
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

The invention relates to combinations comprising an HDAC inhibitor and an immunomodulatory drug for the treatment of multiple myeloma in a subject in need thereof. The combinations may, optionally, further comprise an anti-inflammatory agent, such as dexamethasone. Also provided herein are methods for treating multiple myeloma in a subject in need thereof comprising administering to the subject an effective amount of one of the above combinations.

## Claims

### Claim 1

A pharmaceutical combination for treating multiple myeloma comprising a therapeutically effective amount of a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof, wherein the HDAC6 inhibitor is a compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
Rx, and Ry together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;
each RA is independently C1-6-alkyl, C1-6-alkoxy, halo, OH, —NO2, —CN, or —NH2;
and
m is 0 or 1.

### Claim 2 (depends on 1)

The combination of claim 1, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The combination of claim 1, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The combination of claim 1, wherein the immunomodulatory drug is a compound of Formula III:
or a pharmaceutically acceptable salt thereof,
wherein,
one of X and Y is C═O, the other of X and Y is CH2 or C═O; and
R2 is H or C1-6-alkyl.

### Claim 5 (depends on 4)

The combination of claim 4, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 4)

The combination of claim 4, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The combination of claim 1, wherein the combination further comprises an anti-inflammatory agent.

### Claim 8 (depends on 7)

The combination of claim 7, wherein the anti-inflammatory agent is dexamethasone.

### Claim 9

A pharmaceutical combination for treating multiple myeloma comprising a therapeutically effective amount of a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof, wherein the combination does not include dexamethasone.

### Claim 10 (depends on 9)

The combination of claim 9, wherein the HDAC6 specific inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein,
ring B is aryl or heteroaryl;
R1 is an aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or C1-6-alkyl;
and
R is H or C1-6-alkyl.

### Claim 11 (depends on 10)

The combination of claim 10, wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 10)

The combination of claim 10, wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.

### Claim 13 (depends on 9)

The combination of claim 9, wherein the HDAC6 specific inhibitor is a compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
Rx and Ry together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;
each RA is independently C1-6-alkyl, C1-6-alkoxy, halo, OH, —NO2, —CN, or —NH2;
and
m is 0 or 1.

### Claim 14 (depends on 13)

The combination of claim 13, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 13)

The combination of claim 13, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 9)

The combination of claim 9, wherein the immunomodulatory drug is a compound of Formula III:
or a pharmaceutically acceptable salt thereof,
wherein,
one of X and Y is C═O, the other of X and Y is CH2 or C═O; and
R2 is H or C1-6-alkyl.

### Claim 17 (depends on 16)

The combination of claim 16, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 16)

The combination of claim 16, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 19

A method for treating multiple myeloma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof, wherein the HDAC6 inhibitor is a compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
Rx and Ry together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;
each RA is independently C1-6-alkyl, C1-6-alkoxy, halo, OH, —NO2, —CN, or —NH2;
and
m is 0 or 1.

### Claim 20 (depends on 19)

The method of claim 19, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 21 (depends on 19)

The method of claim 19, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 22 (depends on 19)

The method of claim 19, wherein the immunomodulatory drug is a compound of Formula
or a pharmaceutically acceptable salt thereof,
wherein,
one of X and Y is C═O, the other of X and Y is CH2 or C═O; and
R2 is H or C1-6-alkyl.

### Claim 23 (depends on 22)

The method of claim 22, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 24 (depends on 22)

The method of claim 22, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 25 (depends on 19)

The method of claim 19, wherein the combination further comprises an anti-inflammatory agent.

### Claim 26 (depends on 25)

The method of claim 25, wherein the anti-inflammatory agent is dexamethasone.

### Claim 27

A method for treating multiple myeloma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a pharmaceutical combination comprising a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and an immunomodulatory drug (IMiD) or a pharmaceutically acceptable salt thereof, wherein the combination does not include dexamethasone.

### Claim 28 (depends on 27)

The method of claim 27, wherein the HDAC6 specific inhibitor is a compound of Formula I:
or a pharmaceutically acceptable salt thereof,
wherein,
ring B is aryl or heteroaryl;
R1 is an aryl or heteroaryl, each of which may be optionally substituted by OH, halo, or C1-6-alkyl;
and
R is H or C1-6-alkyl.

### Claim 29 (depends on 28)

The method of claim 28, wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.

### Claim 30 (depends on 28)

The method of claim 28, wherein the compound of Formula I is:
or a pharmaceutically acceptable salt thereof.

### Claim 31 (depends on 27)

The method of claim 27, wherein the HDAC6 specific inhibitor is a compound of Formula II:
or a pharmaceutically acceptable salt thereof,
wherein,
Rx and Ry together with the carbon to which each is attached, form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl;
each RA is independently C1-6-alkyl, C1-6-alkoxy, halo, OH, —NO2, —CN, or —NH2;
and
m is 0 or 1.

### Claim 32 (depends on 31)

The method of claim 31, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 33 (depends on 31)

The method of claim 31, wherein the compound of Formula II is:
or a pharmaceutically acceptable salt thereof.

### Claim 34 (depends on 27)

The method of claim 27, wherein the immunomodulatory drug is a compound of Formula III:
or a pharmaceutically acceptable salt thereof,
wherein,
one of X and Y is C═O, the other of X and Y is CH2 or C═O; and
R2 is H or C1-6-alkyl.

### Claim 35 (depends on 34)

The method of claim 34, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 36 (depends on 34)

The method of claim 34, wherein the compound of Formula III is:
or a pharmaceutically acceptable salt thereof.

### Claim 37 (depends on 19, 27)

The method of claim 19 or 27, wherein the subject was previously refractory to an immunomodulatory drug.

### Claim 38 (depends on 19, 27)

The method of claim 19 or 27, wherein the HDAC inhibitor and the immunomodulatory drug are administered in separate dosage forms.

### Claim 39 (depends on 19, 27)

The method of claim 19 or 27, wherein the HDAC inhibitor and the immunomodulatory drug are administered in a single dosage form.

### Claim 40 (depends on 19, 27)

The method of claim 19 or 27, wherein the HDAC inhibitor and the immunomodulatory drug are administered at different times.

### Claim 41 (depends on 19, 27)

The method of claim 19 or 27, wherein the HDAC inhibitor and the immunomodulatory drug administered at substantially the same time.

### Claim 42

A method for synergistically decreasing cell viability of cancer cells by administering a histone deacetylase (HDAC) specific inhibitor and an immunomodulatory drug (IMiD).

### Claim 43

A method for synergistically increasing apoptosis of cancer cells by administering a histone deacetylase (HDAC) specific inhibitor and an immunomodulatory drug (IMiD).

### Claim 44

A method for decreasing cell proliferation of cancer cells by administering a histone deacetylase (HDAC) specific inhibitor and an immunomodulatory drug (IMiD).

### Claim 45

A method for decreasing MYC and IRF4 expression in cancer cells by administering a histone deacetylase (HDAC) specific inhibitor and an immunomodulatory drug (IMiD).

### Claim 46

A method for increasing P21 expression in cancer cells by administering a histone deacetylase (HDAC) specific inhibitor and an immunomodulatory drug (IMiD).
